1-3 of 3
Eva Cavallin-Ståhl
Close
Sort by
Journal Articles

CNS Disease In Younger Patients (<=60 years) with Aggressive Lymphoma Treated In Trials of the German High Grade Non Hodgkin Lymphoma Study Group (DSHNHL) and the MabThera International Trial (MInT)

Norbert Schmitz, MD, Samira Zeynalova, Bertram Glass, MD, Ulrich Kaiser, MD, Eva Cavallin-Stahl, MD, Max Wolf, MBBS, FRACP, FRCPA, Mathias Haenel, MD, Markus Loeffler, MD, Lorenz Trümper, MD, M. Pfreundschuh
Journal: Blood
Blood (2010) 116 (21): 112.
https://doi.org/10.1182/blood.V116.21.112.112
Published: 2010
Journal Articles

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Niels Murawski, MD, Evelyn Kuhnt, Sandra Grass, MD, Wolfgang Hiddemann, MD, Eva Cavallin-Stahl, MD, Georg Hess, MD, Mathias Witzens-Harig, Ingrid Vasova, MD, Ulrich Jäger, MD, Michal Osowiecki, MD, Scott North, MD, Ruth Pettengell, FRACP, PhD, Viola Pöschel, Markus Löffler, Michael Pfreundschuh, MD
Journal: Blood
Blood (2010) 116 (21): 2826.
https://doi.org/10.1182/blood.V116.21.2826.2826
Published: 2010
Journal Articles

CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial

Clinical Trials & Observations
Eva Ösby, Hans Hagberg, Stein Kvaløy, Lasse Teerenhovi, Harald Anderson, Eva Cavallin-Ståhl, Harald Holte, John Myhre, Hannu Pertovaara, Magnus Björkholm
Journal: Blood
Blood (2003) 101 (10): 3840–3848.
https://doi.org/10.1182/blood-2002-10-3238
Published: 2003